Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine and Decitabine in Older AML and MDS Patients
NCT02141477Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2015
- Primary completion
- Jun 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of homoharringtonine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safe Dose Combination of Omacetaxine (OM) and Decitabine (DAC) at 28 days. Started May 2015; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02141477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141477.